株式会社グローバルインフォメーション
TEL: 044-952-0102
市場調査レポート

滑膜肉腫(SS)- 市場洞察・疫学・市場予測 2028年

Synovial Sarcoma (SS) - Market Insights, Epidemiology and Market Forecast - 2028

発行 DelveInsight Business Research LLP 商品コード 773910
出版日 ページ情報 英文 151 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=110.16円で換算しております。
Back to Top
滑膜肉腫(SS)- 市場洞察・疫学・市場予測 2028年 Synovial Sarcoma (SS) - Market Insights, Epidemiology and Market Forecast - 2028
出版日: 2019年11月01日 ページ情報: 英文 151 Pages
概要

主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における滑膜肉腫(SS)の2017年の罹患数は2,091人、同年の市場規模はおよそ5,943万米ドルと推計されています。

当レポートでは、主要7カ国(米国、英国、ドイツ、フランス、イタリア、スペイン、日本)における滑膜肉腫(SS)市場を調査し、疾病の概要や現行の治療法、上市済み治療薬および新薬のプロファイル、全体および各国の市場動向、疫学的予測、市場規模、部位・年齢・性別・病期別の罹患数の推移と予測、アンメットニーズ、市場の成長要因および障壁などを包括的にまとめています。

目次

第1章 重要洞察

第2章 滑膜肉腫(SS)市場の概要

  • 市場シェア(実績値)
  • 市場シェア(予測値)

第3章 疾病背景と概要

  • イントロダクション
  • 2次タイプ
  • 原因と危険因子
  • 症状
  • 病態生理
  • 遺伝的側面
  • 悪性度分類と病期分類
  • 診断
  • 予後
  • 滑膜肉腫の転移性バイオマーカー

第4章 疫学と患者人口

  • 主な調査結果
  • 主要7カ国の総罹患数
  • 主要7カ国の診断罹患数

第5章 滑膜肉腫(SS)の疫学:国別

  • 米国
    • 仮定と根拠
    • 総罹患数
    • 診断数
    • 診断罹患数:部位別
    • 診断罹患数:性別
    • 診断罹患数:年齢別
    • 診断罹患数:病期別
  • EU5カ国
    • ドイツ
      • 仮定と根拠
      • 総罹患数
      • 診断数
      • 診断罹患数:部位別
      • 診断罹患数:性別
      • 診断罹患数:年齢別
      • 診断罹患数:病期別
    • フランス
    • イタリア
    • スペイン
    • 英国
  • 日本
    • 仮定と根拠
    • 総罹患数
    • 診断数
    • 診断罹患数:部位別
    • 診断罹患数:性別
    • 診断罹患数:年齢別
    • 診断罹患数:病期別

第6章 治療および管理のガイドライン

  • 欧州医学腫瘍学会 - 希少成人固形がんの臨床診療ガイドライン(ESMO-EURACAN-CGP)
  • 軟部肉腫の管理に関する英国のガイドライン
  • 軟部肉腫の診断と治療の改善を目的としたNICEガイドライン

第7章 アンメットニーズ

第8章 上市済み治療薬

  • Yondelis (Trabectadin) :PharmaMar
    • 製品概要
    • 規制のマイルストーン
    • 製造
    • ライセンス
    • 特許
    • 安全性と有効性
    • 製品プロファイル
  • Pazopanib:Novartis
    • 作用機序
    • 製品開発動向

第9章 新薬

  • Tazemetostat:Yondelis
    • 製品概要
    • 製品開発動向
    • 臨床開発
    • 治験情報
    • 製品プロファイル
  • ADP-A2M4:Adaptimmune
  • Anlotinib(AL3818):Advenchen Laboratories

第10章 主要7カ国の滑膜肉腫(SS)市場の分析

  • 主な調査結果
  • 主要7カ国の市場規模

第11章 米国の滑膜肉腫(SS)市場の見通し

  • 市場規模
    • 総市場規模
    • 市場規模:選択治療薬別
    • 市場規模:治療薬別

第12章 EU5カ国の滑膜肉腫(SS)市場の見通し

  • ドイツ
    • 総市場規模
    • 市場規模:選択治療薬別
    • 市場規模:治療薬別
  • フランス
  • イタリア
  • スペイン
  • 英国

第13章 日本の滑膜肉腫(SS)市場の見通し

  • 市場規模
    • 総市場規模
    • 市場規模:選択治療薬別
    • 市場規模:治療薬別

第14章 市場成長要因

第15章 市場の障壁

第16章 付録

  • 調査方法

第17章 DelveInsightのサービス内容

第18章 免責事項

第19章 DelveInsightについて

図表

List of Tables

  • Table 1: Total Incident Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Table 2: Total Diagnosed Incident Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Table 3: Total Incident Cases of Synovial Sarcoma in the US (2017-2028)
  • Table 4: Diagnosed Incidence of SS in the United States (2017-2028)
  • Table 5: Site Specific Diagnose incident cases of SS in the United States (2017-2028)
  • Table 6: Gender Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Table 7: Age Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Table 8: Stage Specific diagnosed Incident of cases of SS in the United States (2017-2028)
  • Table 9: Total Incident Cases of Synovial Sarcoma in Germany (2017-2028)
  • Table 10: Diagnosed Incidence of SS in Germany (2017-2028)
  • Table 11: Site Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 12: Gender Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 13: Age Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Table 14: Stage Specific diagnosed Incident of cases of SS in Germany (2017-2028)
  • Table 15: Total Incident Cases of Synovial Sarcoma in France (2017-2028)
  • Table 16: Diagnosed Incidence of SS in France (2017-2028)
  • Table 17: Site Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 18: Gender Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 19: Age Specific diagnosed incident cases of SS in France (2017-2028)
  • Table 20: Stage Specific diagnosed Incident of cases of SS in France (2017-2028)
  • Table 21: Total Incident Cases of Synovial Sarcoma in Italy (2017-2028)
  • Table 22: Diagnosed Incidence of SS in Italy (2017-2028)
  • Table 23: Site Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 24: Gender Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 25: Age Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Table 26: Stage Specific diagnosed Incident of cases of SS in Italy (2017-2028)
  • Table 27: Total Incident Cases of Synovial Sarcoma in Spain (2017-2028)
  • Table 28: Diagnosed Incidence of SS in Spain (2017-2028)
  • Table 29: Site Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 30: Gender Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 31: Age Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Table 32: Stage Specific diagnosed Incident of cases of SS in Spain (2017-2028)
  • Table 33: Total Incident Cases of Synovial Sarcoma in the UK (2017-2028)
  • Table 34: Diagnosed Incidence of SS in the UK (2017-2028)
  • Table 35: Site Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 36: Gender Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 37: Age Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Table 38: Stage Specific diagnosed Incident of cases of SS in the UK (2017-2028)
  • Table 39: Total Incident Cases of Synovial Sarcoma in Japan (2017-2028)
  • Table 40: Diagnosed Incidence of SS in Japan (2017-2028)
  • Table 41: Site Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Table 42: Gender Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Table 43: Age Specific incident cases of SS in Japan (2017-2028)
  • Table 44: Stage Specific diagnosed Incident of cases of SS in Japan (2017-2028)
  • Table 45: Market Size of Synovial Sarcoma in 7MM in USD Million (2017-2028)
  • Table 46: Total Market Size of Synovial Sarcoma in the United States, USD Million (2017-2028)
  • Table 47: Total Market Size of Synovial Sarcoma by line of therapies in the United States, in USD Million (2017-2028)
  • Table 48: Total Market Size of Synovial Sarcoma by therapies in the United States, USD Million (2017-2028)
  • Table 49: Total Market Size of Synovial Sarcoma in Germany, USD Million (2017-2028)
  • Table 50: Total Market Size of Synovial Sarcoma by line of therapies in Germany, in USD Million (2017-2028)
  • Table 51: Total Market Size of Synovial Sarcoma by therapies in Germany, USD Million (2017-2028)
  • Table 52: Total Market Size of Synovial Sarcoma in France, USD Million (2017-2028)
  • Table 53: Total Market Size of Synovial Sarcoma by line of therapies in France, in USD Million (2017-2028)
  • Table 54: Total Market Size of Synovial Sarcoma by therapies in France, USD Million (2017-2028)
  • Table 55: Total Market Size of Synovial Sarcoma in Italy, USD Million (2017-2028)
  • Table 56: Total Market Size of Synovial Sarcoma by line of therapies in Italy, in USD Million (2017-2028)
  • Table 57: Total Market Size of Synovial Sarcoma by therapies in Italy, USD Million (2017-2028)
  • Table 58: Total Market Size of Synovial Sarcoma in Spain, USD Million (2017-2028)
  • Table 59: Total Market Size of Synovial Sarcoma by line of therapies in Spain, in USD Million (2017-2028)
  • Table 60: Total Market Size of Synovial Sarcoma by therapies in Spain, USD Million (2017-2028)
  • Table 61: Total Market Size of Synovial Sarcoma in The United Kingdom, USD Million (2017-2028)
  • Table 62: Total Market Size of Synovial Sarcoma by line of therapies in The United Kingdom, in USD Million (2017-2028)
  • Table 63: Total Market Size of Synovial Sarcoma by therapies in The United Kingdom, USD Million (2017-2028)
  • Table 64: Total Market Size of Synovial Sarcoma in Japan, USD Million (2017-2028)
  • Table 65: Total Market Size of Synovial Sarcoma by line of therapies in Japan, in USD Million (2017-2028)
  • Table 66: Total Market Size of Synovial Sarcoma by therapies in Japan, USD Million (2017-2028)

List of Figures

  • Figure 1: Subtypes of Synovial Sarcoma
  • Figure 2: Risk factors associated with Synovial Sarcoma
  • Figure 3: SYT-SSX fusion
  • Figure 4: Protein interaction domains involved in synovial sarcoma
  • Figure 5: Relationship between SS18, SS18-SSX and the BAF complex
  • Figure 6: Genomic changes associated with Synovial Sarcoma
  • Figure 7: Biomarkers in Synovial Sarcoma
  • Figure 8: Total Incident Patient Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Figure 9: Total Diagnosed Patient Population of Synovial Sarcomas in the 7MM (2017-2028)
  • Figure 10: Total Incident Cases of Synovial Sarcoma in the US (2017-2028)
  • Figure 11: Diagnosed Incidence of SS in the United States (2017-2028)
  • Figure 12: Site Specific Diagnose incident cases of SS in the United States (2017-2028)
  • Figure 13: Gender Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Figure 14: Age Specific diagnosed incident cases of SS in the United States (2017-2028)
  • Figure 15: Stage Specific diagnosed Incident of cases of SS in the United States (2017-2028)
  • Figure 16: Total Incident Cases of Synovial Sarcoma in Germany (2017-2028)
  • Figure 17: Diagnosed Incidence of SS in Germany (2017-2028)
  • Figure 18: Site Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 19: Gender Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 20: Age Specific diagnosed incident cases of SS in Germany (2017-2028)
  • Figure 21: Stage Specific diagnosed Incident of cases of SS in Germany (2017-2028)
  • Figure 22: Total Incident Cases of Synovial Sarcoma in France (2017-2028)
  • Figure 23: Diagnosed Incidence of SS in France (2017-2028)
  • Figure 24: Site Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 25: Gender Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 26: Age Specific diagnosed incident cases of SS in France (2017-2028)
  • Figure 27: Stage Specific diagnosed Incident of cases of SS in France (2017-2028)
  • Figure 28: Total Incident Cases of Synovial Sarcoma in Italy (2017-2028)
  • Figure 29: Diagnosed Incidence of SS in Italy (2017-2028)
  • Figure 30: Site Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 31: Gender Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 32: Age Specific diagnosed incident cases of SS in Italy (2017-2028)
  • Figure 33: Stage Specific diagnosed Incident of cases of SS in Italy (2017-2028)
  • Figure 34: Total Incident Cases of Synovial Sarcoma in Spain (2017-2028)
  • Figure 35: Diagnosed Incidence of SS in Spain (2017-2028)
  • Figure 36: Site Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 37: Gender Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 38: Age Specific diagnosed incident cases of SS in Spain (2017-2028)
  • Figure 39: Stage Specific diagnosed Incident of cases of SS in Spain (2017-2028)
  • Figure 40: Total Incident Cases of Synovial Sarcoma in the UK (2017-2028)
  • Figure 41: Diagnosed Incidence of SS in the UK (2017-2028)
  • Figure 42: Site Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 43: Gender Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 44: Age Specific diagnosed incident cases of SS in the UK (2017-2028)
  • Figure 45: Stage Specific diagnosed Incident of cases of SS in the UK (2017-2028)
  • Figure 46: Total Incident Cases of Synovial Sarcoma in Japan (2017-2028)
  • Figure 47: Diagnosed Incidence of SS in Japan (2017-2028)
  • Figure 48: Site Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Figure 49: Gender Specific diagnosed incident cases of SS in Japan (2017-2028)
  • Figure 50: Age Specific incident cases of SS in Japan (2017-2028)
  • Figure 51: Stage Specific diagnosed Incident of cases of SS in Japan (2017-2028)
  • Figure 52: The Multi-disciplinary judgment approach
  • Figure 53: Management of Localized clinically resectable STSs
  • Figure 54: Synovial Sarcoma unmet needs
  • Figure 55: Market Size of Synovial Sarcoma in 7MM in USD Million (2017-2028)
  • Figure 56: Total Market Size of Synovial Sarcoma in the United States, USD Millions (2017-2028)
  • Figure 57: Total Market Size of Synovial Sarcoma by line of therapies the United States, in USD Million (2017-2028)
  • Figure 58:Total Market Size of Synovial Sarcoma by therapies in the United States, USD Millions (2017-2028)
  • Figure 59: Total Market Size of Synovial Sarcoma in Germany, USD Millions (2017-2028)
  • Figure 60: Total Market Size of Synovial Sarcoma by line of therapies Germany, in USD Million (2017-2028)
  • Figure 61:Total Market Size of Synovial Sarcoma by therapies in Germany, USD Millions (2017-2028)
  • Figure 62: Total Market Size of Synovial Sarcoma in France, USD Millions (2017-2028)
  • Figure 63: Total Market Size of Synovial Sarcoma by line of therapies France, in USD Million (2017-2028)
  • Figure 64:Total Market Size of Synovial Sarcoma by therapies in France, USD Millions (2017-2028)
  • Figure 65: Total Market Size of Synovial Sarcoma in Italy, USD Millions (2017-2028)
  • Figure 66: Total Market Size of Synovial Sarcoma by line of therapies Italy, in USD Million (2017-2028)
  • Figure 67:Total Market Size of Synovial Sarcoma by therapies in Italy, USD Millions (2017-2028)
  • Figure 68: Total Market Size of Synovial Sarcoma in Spain, USD Millions (2017-2028)
  • Figure 69: Total Market Size of Synovial Sarcoma by line of therapies Spain, in USD Million (2017-2028)
  • Figure 70:Total Market Size of Synovial Sarcoma by therapies in Spain, USD Millions (2017-2028)
  • Figure 71: Total Market Size of Synovial Sarcoma in The United Kingdom, USD Millions (2017-2028)
  • Figure 72: Total Market Size of Synovial Sarcoma by line of therapies The United Kingdom, in USD Million (2017-2028)
  • Figure 73:Total Market Size of Synovial Sarcoma by therapies in The United Kingdom, USD Millions (2017-2028)
  • Figure 74: Total Market Size of Synovial Sarcoma in Japan, USD Millions (2017-2028)
  • Figure 75: Total Market Size of Synovial Sarcoma by line of therapies Japan, in USD Million (2017-2028)
  • Figure 76:Total Market Size of Synovial Sarcoma by therapies in Japan, USD Millions (2017-2028)
  • Figure 77: Synovial Sarcoma market drivers
  • Figure 78: Synovial Sarcoma market barriers
目次
Product Code: DIMI0472

DelveInsight's 'Synovial Sarcoma (SS) - Market Insights, Epidemiology and Market Forecast-2028 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of SS in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Synovial Sarcoma from 2017 to 2028 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028

Synovial Sarcoma (SS) - Disease Understanding and Treatment Algorithm

Synovial sarcoma (SS) is a rare malignancy of mesenchymal origin, accounting for approximately 8-10% of all soft tissue sarcomas (STS). Synovial Sarcoma is generally divided into three histological subtypes: monophasic, biphasic, and poorly differentiated and can affect patients of any age, although it is most common in adolescents and adults younger than 30 years of age. In the adolescent patient population, SS is considered the most common sarcoma subtype. The exact underlying cause of synovial sarcoma is poorly understood. However, studies show that a certain genetic change is identified in more than maximum number of cases.

The DelveInsight Synovial Sarcoma (SS) market report gives the thorough understanding of the Synovial Sarcoma by including details such as disease definition, classification, symptoms, genetics factors, risk factors, grading and staging, biomarkers, pathophysiology, and diagnostic trends. It also provides treatment algorithms and treatment guidelines for Synovial Sarcoma in the US, Europe and Japan.

Synovial Sarcoma Epidemiology

The Synovial Sarcoma (SS) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total incident cases , diagnosed incident cases, Site-specific incidence, gender-specific incidence, age-specific incidence, stage-specific incidence) scenario of synovial sarcoma in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

According to DelveInsight, the total number of Incident cases of Synovial Sarcoma (SS) in 7 MM was found to be 2091 in the year 2017.

Synovial Sarcoma Drug Chapters

This segment of the Synovial Sarcoma report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

Surgery remains the cornerstone of treatment and the only curative locoregional approach of localized resectable Soft Tissue Sarcoma including Synovial Sarcoma cases. While considering the overall disease management perspective, first-line treatment usually consists of wide margin surgery plus radiotherapy. Chemotherapy forms the first line of defense to treat most metastatic sarcomas with SS being no exception. As per latest treatment paradigms chemotherapy regimen is administered for a fixed number of cycles followed by a watchful waiting approach to assess the optimum response.

Synovial Sarcoma Market Outlook

The Synovial Sarcoma market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the market of Synovial Sarcoma in 7MM was found to be USD 59.43 Million in 2017, and is expected to increase during the course of the study period (2017-2028). Among the 7MM, the United States accounts for the largest market size of Synovial Sarcoma, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Synovial Sarcoma Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2028. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Synovial Sarcoma Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Synovial Sarcoma Report Key Strengths

  • 10 Years Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Key Cross Competition
  • Market Size by Therapies
  • Drugs Uptake

Synovial Sarcoma Report Assessment

  • Pipeline Product Profiles
  • Key Products and Key Players
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Synovial Sarcoma market
  • Organize sales and marketing efforts by identifying the best opportunities for A Synovial Sarcoma market
  • To understand the future market competition in the Synovial Sarcoma market.

Table of Contents

1. Key Insights

2. Synovial Sarcoma Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of Synovial Sarcoma Market in 2017
  • 2.2. Market Share (%) Distribution of Synovial Sarcoma Market in 2028

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Subtypes
  • 3.3. Causes and risk factors
  • 3.4. Symptoms
  • 3.5. Pathophysiology
  • 3.6. Genetic aspect of synovial sarcoma
  • 3.7. Grading and staging of soft tissue sarcoma
  • 3.8. Diagnosis
  • 3.9. Prognosis
  • 3.10. Metastatic biomarkers in Synovial Sarcoma

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. 7MM Total Incident Patient Population of Synovial Sarcoma
  • 4.3. 7MM Diagnosed Incident Patient Population of Synovial Sarcoma

5. Country Wise-Epidemiology of Synovial Sarcoma

  • 5.1. United States
    • 5.1.1. Assumptions and Rationale
    • 5.1.2. Total Incident Cases of SS
    • 5.1.3. Diagnosed Incidence of SS
    • 5.1.4. Site Specific Diagnose incident cases of SS
    • 5.1.5. Gender Specific diagnosed incident cases of SS
    • 5.1.6. Age Specific diagnosed incident cases of SS
    • 5.1.7. Stage Specific diagnosed Incident of cases of SS
  • 5.2. EU5 Countries
    • 5.2.1. Assumptions and Rationale
  • 5.3. Germany
    • 5.3.1. Total Incident Cases of SS
    • 5.3.2. Diagnosed Incidence of SS
    • 5.3.3. Site Specific diagnosed incident cases of SS
    • 5.3.4. Gender Specific diagnosed incident cases of SS
    • 5.3.5. Age Specific diagnosed incident cases of SS
    • 5.3.6. Stage Specific diagnosed Incident of cases of SS
  • 5.4. France
    • 5.4.1. Total Incident Cases of SS
    • 5.4.2. Diagnosed Incidence of SS
    • 5.4.3. Site Specific diagnosed incident cases of SS
    • 5.4.4. Gender Specific diagnosed incident cases of SS
    • 5.4.5. Age Specific diagnosed incident cases of SS
    • 5.4.6. Stage Specific diagnosed Incident of cases of SS
  • 5.5. Italy
    • 5.5.1. Total Incident Cases of SS
    • 5.5.2. Diagnosed Incidence of SS
    • 5.5.3. Site Specific diagnosed incident cases of SS
    • 5.5.4. Gender Specific diagnosed incident cases of SS
    • 5.5.5. Age Specific diagnosed incident cases of SS
    • 5.5.6. Stage Specific diagnosed Incident of cases of SS
  • 5.6. Spain
    • 5.6.1. Total Incident Cases of SS
    • 5.6.2. Diagnosed Incidence of SS
    • 5.6.3. Site Specific diagnosed incident cases of SS
    • 5.6.4. Gender Specific diagnosed incident cases of SS
    • 5.6.5. Age Specific diagnosed incident cases of SS
    • 5.6.6. Stage Specific diagnosed Incident of cases of SS
  • 5.7. United Kingdom
    • 5.7.1. Total Incident Cases of SS
    • 5.7.2. Diagnosed Incidence of SS
    • 5.7.3. Site Specific diagnosed incident cases of SS
    • 5.7.4. Gender Specific incident cases of SS
    • 5.7.5. Age Specific diagnosed incident cases of SS
    • 5.7.6. Stage Specific diagnosed Incident of cases of SS
  • 5.8. Japan
    • 5.8.1. Assumptions and Rationale
    • 5.8.2. Total Incident Cases of SS
    • 5.8.3. Diagnosed Incidence of SS
    • 5.8.4. Site Specific diagnosed incident cases of SS
    • 5.8.5. Gender Specific diagnosed incident cases of SS
    • 5.8.6. Age Specific diagnosed incident cases of SS
    • 5.8.7. Stage Specific diagnosed Incident of cases of SS

6. Guidelines for Treatment/ Management of Soft-Tissue Sarcoma

  • 6.1. European Society for Medical Oncology- European Reference Network for rare adult solid cancers Clinical Practice Guidelines (ESMO-EURACAN-CGP): for Soft-Tissue Sarcoma
  • 6.2. UK Guidelines for Management of Soft-tissue Sarcomas
  • 6.3. NICE Guidelines for Improving Diagnosis and Treatment of Soft-Tissue Sarcoma

7. Unmet needs

8. Marketed Drugs

  • 8.1. Yondelis (Trabectadin) - PharmaMar
    • 8.1.1. Product description
    • 8.1.2. Regulatory Milestones
    • 8.1.3. Manufacturing
    • 8.1.4. Licensing
    • 8.1.5. Patent
    • 8.1.6. Safety and Efficacy
    • 8.1.7. Product Profile
  • 8.2. Pazopanib: Novartis
    • 8.2.1. Product description
    • 8.2.2. Mechanism of action
    • 8.2.3. Regulatory Milestones
    • 8.2.4. Product Development Activities
    • 8.2.5. Safety and Efficacy
    • 8.2.6. Product Profile

9. Emerging drugs

  • 9.1. Tazemetostat: Yondelis
    • 9.1.1. Product Description
    • 9.1.2. Product Development Activities
    • 9.1.3. Clinical development
    • 9.1.4. Clinical Trials Information
    • 9.1.5. Product Profile
  • 9.2. ADP-A2M4: Adaptimmune
    • 9.2.1. Product Description
    • 9.2.2. Product Development Activities
    • 9.2.3. Clinical development
    • 9.2.4. Clinical Trials Information
    • 9.2.5. Product Profile
  • 9.3. Anlotinib (AL3818): Advenchen Laboratories
    • 9.3.1. Product Description
    • 9.3.2. Product Development Activities
    • 9.3.3. Clinical development
    • 9.3.4. Clinical Trials Information
    • 9.3.5. Product Profile

10. Synovial Sarcoma: 7 Major Market Analysis

  • 10.1. Key Findings
  • 10.2. Market Size of Synovial Sarcoma in 7MM

11. The United States Market Outlook

  • 11.1. United States Market Size
    • 11.1.1. Total Market Size of Synovial Sarcoma
    • 11.1.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 11.1.3. Total Market Size of Synovial Sarcoma by therapies

12. EU-5 Countries: Market Outlook

  • 12.1. Germany
    • 12.1.1. Total Market Size of Synovial Sarcoma
    • 12.1.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.1.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.2. France
    • 12.2.1. Total Market Size of Synovial Sarcoma
    • 12.2.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.2.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.3. Italy
    • 12.3.1. Total Market Size of Synovial Sarcoma
    • 12.3.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.3.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.4. Spain
    • 12.4.1. Total Market Size of Synovial Sarcoma
    • 12.4.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.4.3. Total Market Size of Synovial Sarcoma by therapies
  • 12.5. The United Kingdom
    • 12.5.1. Total Market Size of Synovial Sarcoma
    • 12.5.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 12.5.3. Total Market Size of Synovial Sarcoma by therapies

13. Japan: Market Outlook

  • 13.1. Japan market Size
    • 13.1.1. Total Market Size of Synovial Sarcoma
    • 13.1.2. Total Market Size of Synovial Sarcoma by line of therapies
    • 13.1.3. Total Market Size of Synovial Sarcoma by therapies

14. Market Drivers

15. Market Barriers

16. Appendix

  • 16.1. Report Methodology

17. DelveInsight Capabilities

18. Disclaimer

19. About DelveInsight

Back to Top